Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Abroad (travel likely)RecruitingPHASE3

Conditions

Advanced Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Degan Lu, Jinan, Shandong, China
Contact: Study coordinator (Degan Lu, professor) · deganlu@126.com · 18753157623

Study leads

Degan Lu
Principal Investigator
he First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Fountain Valley, United States · Los Alamitos, United States

Nurse-Led Caregiver Support for Older Adults With Advanced Lung Cancer

Non-Small Cell Lung Cancer · Advanced Lung Cancer · Caregiver Burden

Abroad (travel likely)Recruiting

Taipei, Taiwan · Taipei, Taiwan

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

Non-Small Cell Carcinoma of Lung · Immunotherapy · Advanced Non-Small Cell Lung Cancer

Abroad (travel likely)Recruiting

Beijing, China

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Philadelphia, United States